BioVaxys Technology Corp. (CSE:BIOV)
Canada
· Delayed Price · Currency is CAD 0.190
-0.020 (-9.52%)
Dec 5, 2025, 3:59 PM EST
BioVaxys Technology Balance Sheet
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | 2019 |
| Cash & Equivalents | 0 | 0.21 | 0 | 0.14 | 0.59 | 2.42 | Upgrade
|
| Cash & Short-Term Investments | 0 | 0.21 | 0 | 0.14 | 0.59 | 2.42 | Upgrade
|
| Cash Growth | -99.17% | 21579.22% | -99.31% | -76.08% | -75.52% | 958.21% | Upgrade
|
| Other Receivables | 0.49 | 0.44 | 0.09 | 0.05 | 0.05 | 0.05 | Upgrade
|
| Receivables | 0.49 | 0.44 | 0.09 | 0.21 | 0.13 | 0.05 | Upgrade
|
| Prepaid Expenses | 0.9 | 0.65 | 0.02 | 0.36 | 0.15 | 0.59 | Upgrade
|
| Total Current Assets | 1.39 | 1.3 | 0.11 | 0.71 | 0.87 | 3.06 | Upgrade
|
| Other Intangible Assets | - | - | - | - | 7.4 | 7.4 | Upgrade
|
| Total Assets | 1.39 | 1.3 | 0.11 | 0.87 | 8.5 | 10.46 | Upgrade
|
| Accounts Payable | 2.47 | 1.56 | 2.66 | 1.31 | 0.22 | 0.75 | Upgrade
|
| Accrued Expenses | 2.42 | 1.6 | 0.83 | 0.33 | 0.11 | 0.15 | Upgrade
|
| Short-Term Debt | 0.13 | 0.07 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 5.03 | 3.22 | 3.49 | 1.64 | 0.33 | 0.9 | Upgrade
|
| Total Liabilities | 5.03 | 3.22 | 3.49 | 1.64 | 0.33 | 0.9 | Upgrade
|
| Common Stock | 28.59 | 27.04 | 21.99 | 17.05 | 14.76 | 10.75 | Upgrade
|
| Retained Earnings | -34.55 | -31.25 | -27.3 | -19.61 | -8.02 | -1.56 | Upgrade
|
| Comprehensive Income & Other | 2.32 | 2.29 | 1.93 | 1.78 | 1.44 | 0.37 | Upgrade
|
| Shareholders' Equity | -3.64 | -1.92 | -3.37 | -0.77 | 8.18 | 9.56 | Upgrade
|
| Total Liabilities & Equity | 1.39 | 1.3 | 0.11 | 0.87 | 8.5 | 10.46 | Upgrade
|
| Total Debt | 0.13 | 0.07 | - | - | - | - | Upgrade
|
| Net Cash (Debt) | -0.13 | 0.14 | 0 | 0.14 | 0.59 | 2.42 | Upgrade
|
| Net Cash Growth | - | 14610.95% | -99.31% | -76.08% | -75.52% | 958.21% | Upgrade
|
| Net Cash Per Share | -0.00 | 0.01 | 0.00 | 0.01 | 0.07 | 0.86 | Upgrade
|
| Filing Date Shares Outstanding | 29.15 | 29.15 | 22.02 | 11.53 | 9.97 | 8.15 | Upgrade
|
| Total Common Shares Outstanding | 29.15 | 26.21 | 14.51 | 10.88 | 9.22 | 7.41 | Upgrade
|
| Working Capital | -3.64 | -1.92 | -3.37 | -0.92 | 0.55 | 2.16 | Upgrade
|
| Book Value Per Share | -0.12 | -0.07 | -0.23 | -0.07 | 0.89 | 1.29 | Upgrade
|
| Tangible Book Value | -3.64 | -1.92 | -3.37 | -0.77 | 0.78 | 2.16 | Upgrade
|
| Tangible Book Value Per Share | -0.12 | -0.07 | -0.23 | -0.07 | 0.08 | 0.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.